Skip to main content
Proper Name
Hepatitis A Vaccine, Inactivated
For the prevention of disease cause by hepatitis A virus (HAV) in persons 12 months of age and older.

VAQTA is an inactivated whole virus vaccine derived from hepatitis A virus grown in cell culture in human MRC-5 diploid fibroblasts. 

Key Regulatory Milestones

1996 - VAQTA licensed in the U.S.

07/19/2012 - PDUFA goal date

10/23/2020 - FDA approval date

Advisory Committee

There were no product-specific concerns that would have benefited from an advisory committee discussion.

Advanced Facts